← Leaderboards
Roger S Lo
University Of California Los Angeles
$11,431,145
Attributed
$12,085,097
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,085,097 · 10
By mechanism
R01$5,521,249 · 2
P01$4,157,884 · 3
U54$1,081,326 · 2
R21$764,118 · 2
K22$560,520 · 1
Top collaborators
- Alan Jackson Tackett2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Paul S Mischel$15,265,453
- James S. Economou$9,911,213
- Antoni Ribas$28,929,216
- Gatien Moriceau$1,907,235
- Robert M Prins$8,963,397
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMelanomaTumorResistancePathway InteractionsCombinatorialMelanoma CellResponseResistance MechanismMutationMap Kinase GeneCell LineMeksInsightTissuesBaseTargeted TreatmentPhenotypeEvolutionMutantNeoplastic CellSignal TransductionMalignant NeoplasmsCancer Therapy
Grant awards (35)
Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistance$647,072
R01 · FY2025 · CA · contact PI
Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistance$393,750
R01 · FY2025 · CA · contact PI
Core 1: Mouse Model and Tissue Biobank Core$251,669
U54 · FY2025 · CA · contact PI
Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistance$660,833
R01 · FY2024 · CA · contact PI
Project 1: Strategies to enhance MEK inhibitor efficacy in MUTNRAS melanoma$492,026
P01 · FY2024 · CA · contact PI
Preventing MAPK inhibitor resistance in melanoma by targeting genomic instability and immune resistance$393,750
R01 · FY2024 · CA · contact PI
Core 1: Mouse Model and Tissue Biobank Core$256,772
U54 · FY2024 · CA · contact PI
Project 1: Strategies to enhance MEK inhibitor efficacy in MUTNRAS melanoma$507,563
P01 · FY2023 · CA · contact PI
Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma$363,090
R01 · FY2023 · CA · contact PI
Core 1: Mouse Model and Tissue Biobank Core$250,014
U54 · FY2023 · CA · contact PI
Project 1: Strategies to enhance MEK inhibitor efficacy in MUTNRAS melanoma$507,564
P01 · FY2022 · CA · contact PI
Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma$363,090
R01 · FY2022 · CA · contact PI
Core 1: Mouse Model and Tissue Biobank Core$322,871
U54 · FY2022 · CA · contact PI
Understanding PD-L1/L2 protein regulation, detection and signaling to predict melanoma therapeutic sensitivity$214,414
R21 · FY2022 · CA · contact PI
Project 1: Strategies to enhance MEK inhibitor efficacy in MUTNRAS melanoma$517,920
P01 · FY2021 · CA · contact PI
Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma$370,500
R01 · FY2021 · CA · contact PI
Understanding PD-L1/L2 protein regulation, detection and signaling to predict melanoma therapeutic sensitivity$182,325
R21 · FY2021 · CA · contact PI
Project 1: Strategies to enhance MEK inhibitor efficacy in MUTNRAS melanoma$517,920
P01 · FY2020 · CA · contact PI
Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma$370,500
R01 · FY2020 · CA · contact PI
Combinatorial Targeting of Epigenomic and Microenvironmental Pathways to Suppress MAPK Inhibitor Resistance in Melanoma$370,500
R01 · FY2019 · CA · contact PI
Exploiting Drug Addiction to Improve the Efficacy of MAPK Pathway Targeted Therapy in BRAF and NRAS Mutant Melanoma$164,560
R21 · FY2019 · CA · contact PI
Exploiting Drug Addiction to Improve the Efficacy of MAPK Pathway Targeted Therapy in BRAF and NRAS Mutant Melanoma$202,819
R21 · FY2018 · CA · contact PI
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMAS$325,178
P01 · FY2017 · CA · contact PI
Overcoming acute, adaptive BRAF inhibitor resistance in melanoma$319,550
R01 · FY2017 · CA · contact PI
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMAS$325,178
P01 · FY2016 · CA · contact PI
Overcoming acute, adaptive BRAF inhibitor resistance in melanoma$319,550
R01 · FY2016 · CA · contact PI
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMAS$325,178
P01 · FY2015 · CA · contact PI
Overcoming acute, adaptive BRAF inhibitor resistance in melanoma$319,550
R01 · FY2015 · CA · contact PI
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMAS$315,423
P01 · FY2014 · CA · contact PI
Overcoming acute, adaptive BRAF inhibitor resistance in melanoma$309,964
R01 · FY2014 · CA · contact PI
TARGETED COMBINATORIAL TREATMENT OF BRAF MELANOMAS$323,934
P01 · FY2013 · CA · contact PI
Overcoming acute, adaptive BRAF inhibitor resistance in melanoma$319,550
R01 · FY2013 · CA · contact PI
Augmenting Melanoma Response to B-Raf V600E Targeting$186,840
K22 · FY2012 · CA · contact PI
Augmenting Melanoma Response to B-Raf V600E Targeting$186,840
K22 · FY2011 · CA · contact PI
Augmenting Melanoma Response to B-Raf V600E Targeting$186,840
K22 · FY2010 · CA · contact PI